Sex Differences in the Effects of a Biological Drug for Rheumatoid Arthritis on Depressive State.

Q4 Medicine

Open Rheumatology Journal Pub Date : 2015-07-10 eCollection Date: 2015-01-01 DOI:10.2174/1874312901409010051

Takahiro Tokunaga, Yusuke Miwa, Airi Nishimi, Shinichiro Nishimi, Mayu Saito, Nao Oguro, Yoko Miura, Sho Ishii, Ryo Takahashi, Tsuyoshi Kasama, Kenji Sanada

{"title":"Sex Differences in the Effects of a Biological Drug for Rheumatoid Arthritis on Depressive State.","authors":"Takahiro Tokunaga, Yusuke Miwa, Airi Nishimi, Shinichiro Nishimi, Mayu Saito, Nao Oguro, Yoko Miura, Sho Ishii, Ryo Takahashi, Tsuyoshi Kasama, Kenji Sanada","doi":"10.2174/1874312901409010051","DOIUrl":null,"url":null,"abstract":"Objective: Sex-specific medicine has attracted attention in recent years, but no report on rheumatoid arthritis (RA) has examined sex differences in the effectiveness of biologics on activities of daily living (ADL), quality of life (QOL), or depressive state.Methods: The study subjects were 161 RA patients (female: 138; male: 23) attending regular doctor visits at our hospital. We compared the changes in disease activity, which was evaluated using the simplified disease activity index (SDAI), ADL (using the modified health assessment questionnaire; mHAQ), QOL (using short form-36; SF-36), and the Hamilton Depression Rating Scale (HAM-D) for RA patients between each sex over a six-month observation period while administering biologic treatment.Results: The female patients reported significant improvements in the following metrics: SDAI: from 22.1 ± 11.9 to 8.9 ± 7.8 (p < 0.001); mHAQ: from 0.46 ± 0.50 to 0.32 ± 0.45 (p < 0.001); and HAM-D: from 6.2 ± 4.8 to 3.8 ± 4.1 (p < 0.001). Moreover, all eight items of the SF-36 were significantly improved (p < 0.01). In contrast, the male patients improved on the SDAI (from 27.9 ± 11.7 to 12.7 ± 8.6 (p < 0.001)), but we did not observe significant improvements in the mHAQ or HAM-D scores or in any items on the SF-36.Conclusion: Both male and female patients with RA improved when using a biological drug. Sex differences in the improvement of depressive state were observed.","PeriodicalId":39124,"journal":{"name":"Open Rheumatology Journal","volume":"9 ","pages":"51-6"},"PeriodicalIF":0.0000,"publicationDate":"2015-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/70/31/TORJ-9-51.PMC4541463.pdf","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Rheumatology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874312901409010051","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 5

Abstract

Objective: Sex-specific medicine has attracted attention in recent years, but no report on rheumatoid arthritis (RA) has examined sex differences in the effectiveness of biologics on activities of daily living (ADL), quality of life (QOL), or depressive state.

Methods: The study subjects were 161 RA patients (female: 138; male: 23) attending regular doctor visits at our hospital. We compared the changes in disease activity, which was evaluated using the simplified disease activity index (SDAI), ADL (using the modified health assessment questionnaire; mHAQ), QOL (using short form-36; SF-36), and the Hamilton Depression Rating Scale (HAM-D) for RA patients between each sex over a six-month observation period while administering biologic treatment.

Results: The female patients reported significant improvements in the following metrics: SDAI: from 22.1 ± 11.9 to 8.9 ± 7.8 (p < 0.001); mHAQ: from 0.46 ± 0.50 to 0.32 ± 0.45 (p < 0.001); and HAM-D: from 6.2 ± 4.8 to 3.8 ± 4.1 (p < 0.001). Moreover, all eight items of the SF-36 were significantly improved (p < 0.01). In contrast, the male patients improved on the SDAI (from 27.9 ± 11.7 to 12.7 ± 8.6 (p < 0.001)), but we did not observe significant improvements in the mHAQ or HAM-D scores or in any items on the SF-36.

Conclusion: Both male and female patients with RA improved when using a biological drug. Sex differences in the improvement of depressive state were observed.

Abstract Image

查看原文本刊更多论文

类风湿关节炎生物药物对抑郁状态影响的性别差异。

目的:性别特异性医学近年来备受关注，但类风湿关节炎(RA)生物制剂对日常生活活动(ADL)、生活质量(QOL)或抑郁状态有效性的性别差异尚未见报道。方法:研究对象为161例RA患者(女性138例;男:定期到我们医院看医生。我们比较了疾病活动性的变化，使用简化疾病活动性指数(SDAI)， ADL(使用改进的健康评估问卷;mHAQ)， QOL(使用简写-36;SF-36)和汉密尔顿抑郁评定量表(HAM-D)，在给予生物治疗的6个月观察期内，男女RA患者之间进行比较。结果:女性患者报告了以下指标的显著改善:SDAI从22.1±11.9降至8.9±7.8 (p < 0.001);mHAQ:从0.46±0.50到0.32±0.45 (p < 0.001);HAM-D从6.2±4.8降至3.8±4.1 (p < 0.001)。SF-36 8项得分均显著提高(p < 0.01)。相比之下，男性患者的SDAI得到改善(从27.9±11.7到12.7±8.6 (p < 0.001))，但我们没有观察到mHAQ或HAM-D评分或SF-36的任何项目有显著改善。结论:男性和女性RA患者在使用生物药物后均有改善。观察抑郁状态改善的性别差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Rheumatology Journal Medicine-Rheumatology

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： ENTHAM Open publishes a number of peer-reviewed, open access journals. These free-to-view online journals cover all major disciplines of science, medicine, technology and social sciences. BENTHAM Open provides researchers a platform to rapidly publish their research in a good-quality peer-reviewed journal. All peer-reviewed accepted submissions meeting high research and ethical standards are published with free access to all.